SARS-CoV-2 (501.V2) stabilized spike
Showing the single result
Recent Posts
- Influenza antigens for Northern Hemisphere’s 2023-2024 flu season
- Bacterial Antigens, Antibodies, and custom solutions for your research needs
- The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein
- The Native Antigen Company introduces new range of influenza antigens
- The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant
Archives
- February 2023
- December 2022
- November 2022
- October 2022
- August 2022
- January 2022
- November 2021
- August 2021
- July 2021
- June 2021
- March 2021
- November 2020
- October 2020
- August 2020
- July 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
Categories
- Adenovirus
- Borrelia
- Cancer
- Clostridium
- CMV
- Coronaviruses
- COVID-19
- Dengue Virus
- Disease insight
- Disease trends
- Ebola virus
- Electron Microscopy
- Flaviviruses
- HIV
- Immunoassays
- Immunofluorescence
- Influenza
- Lassa Fever virus
- Legionella
- Malaria
- Measles
- Neglected Tropical Diseases
- Neisseria gonorrhoeae
- New products
- Nipah Virus
- Pertussis Toxin
- Plasmodia
- Research
- Services
- Sustainability
- Tick-Borne Disease
- Toxins
- Uncategorised
- Vaccines
- Yellow Fever virus
- Zika